2017 Compounding Pharmacies HIV Treatment and Prevention Agents 
Pharmacy Times
AUGUST 13, 2025
The recent approval of brentuximab vedotin (BV, Adcetris; Seagen Inc) in combination with lenalidomide (Len, Revlimid; Bristol Myers Squibb) and a rituximab (R; BV-R2) product is a pivotal moment in cancer therapeutics and provides an alternative treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Pharmacy Times
JULY 19, 2025
Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action. Jansen, PharmD Candidate , Mark A.
Pharmacy Times
JULY 8, 2025
Further research is needed on the clinical impact, treatment longevity, and cost implications of biosimilar use in pediatric IBD. 2 Tumor necrosis factor alpha inhibitors (anti-TNFs) have become both first- and second-line therapies for the treatment of pediatric patients with Crohn disease and ulcerative colitis.
Expert insights. Personalized for you.
Let's personalize your content